Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-05-01 to 2019-10-31|
Take a look of project's partnership.
ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.
Optimised auxiliary electronics system for quantum computing researchRead More
Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired usersRead More
MANUBACK, the smart garment for operator protection in the field of Manual Handling of GoodsRead More